Status:
COMPLETED
Observational Study Describing Conditions for Administering Slow-acting Insulin Analogue With Oral Antidiabetic Agents in Type 2 Diabetes on Blood Glucose Control
Lead Sponsor:
Novo Nordisk A/S
Conditions:
Diabetes
Diabetes Mellitus, Type 2
Eligibility:
All Genders
40+ years
Brief Summary
This study is conducted in Europe. The aim of this observational study is to describe the conditions for the concomitant administration of a slow-acting insulin analogue with oral antidiabetics (OADs)...
Eligibility Criteria
Inclusion
- Type 2 diabetes
- HbA1c level greater than 7% despite treatment with two (or three) oral antidiabetic drugs (OADs) at an optimal dose level
- Patient agreeing to take part in the study and capable of completing a self-questionnaire.
Exclusion
- Hypersensitivity to insulin or to one of the excipients
- Treatment with insulin for at least 6 months
- Participant in a clinical trial for diabetes on entry into the observational study
Key Trial Info
Start Date :
June 1 2007
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
November 1 2008
Estimated Enrollment :
2745 Patients enrolled
Trial Details
Trial ID
NCT00700960
Start Date
June 1 2007
End Date
November 1 2008
Last Update
January 31 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Novo Nordisk Investigational Site
Paris La Défense, France, 92936